RaQualia Pharma Inc. (TYO:4579)

RaQualia Pharma Cash Flow Statement

Financials in millions JPY. Fiscal year is January - December.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Net Income	437	-357	-294	851	880
Depreciation & Amortization	487	401	175	147	141
Loss (Gain) From Sale of Investments	-	-3	-	35	-16
Other Operating Activities	-131	-100	-128	-203	-81
Change in Accounts Receivable	-1,239	-85	-	603	-674
Change in Inventory	7	3	-139	2	-4
Change in Accounts Payable	76	-98	-134	111	136
Change in Other Net Operating Assets	9	419	-198	-66	-16
Operating Cash Flow	-354	180	-718	1,480	366
Operating Cash Flow Growth	-	-	-	304.37%	-
Capital Expenditures	-67	-96	-205	-31	-92
Cash Acquisitions	-	-3,879	-	-	-
Sale (Purchase) of Intangibles	-7	-19	-17	-	-13
Investment in Securities	200	158	90	-15	-174
Other Investing Activities	-2	171	-3	-1	-
Investing Cash Flow	124	-3,665	-135	-47	-279
Short-Term Debt Issued	-	400	-	-	10
Long-Term Debt Issued	-	3,357	50	13	-
Total Debt Issued	-	3,757	50	13	10
Short-Term Debt Repaid	-	-400	-	-	-10
Long-Term Debt Repaid	-512	-387	-11	-2	-
Total Debt Repaid	-512	-787	-11	-2	-10
Net Debt Issued (Repaid)	-512	2,970	39	11	-
Issuance of Common Stock	1,019	80	805	4	1
Other Financing Activities	-129	-68	-51	-44	-17
Financing Cash Flow	378	2,982	793	-29	-16
Foreign Exchange Rate Adjustments	-45	-20	45	35	109
Miscellaneous Cash Flow Adjustments	-1	1	1	-1	-1
Net Cash Flow	102	-522	-14	1,438	179
Free Cash Flow	-421	84	-923	1,449	274
Free Cash Flow Growth	-	-	-	428.83%	-
Free Cash Flow Margin	-10.58%	2.70%	-48.55%	49.66%	9.87%
Free Cash Flow Per Share	-17.50	3.88	-42.72	69.06	13.06
Cash Interest Paid	59	42	6	6	1
Cash Income Tax Paid	138	100	109	183	76
Levered Free Cash Flow	-485	415.63	-694	1,172	64.88
Unlevered Free Cash Flow	-448.13	441.88	-689.63	1,176	65.5
Change in Working Capital	-1,147	239	-471	650	-558

Updated Dec 31, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.